BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hastak K, Alli E, Ford JM. Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin. Cancer Res. 2010;70:7970-7980. [PMID: 20798217 DOI: 10.1158/0008-5472.can-09-4521] [Cited by in Crossref: 114] [Cited by in F6Publishing: 68] [Article Influence: 10.4] [Reference Citation Analysis]
Number Citing Articles
1 Bower JJ, Vance LD, Psioda M, Smith-Roe SL, Simpson DA, Ibrahim JG, Hoadley KA, Perou CM, Kaufmann WK. Patterns of cell cycle checkpoint deregulation associated with intrinsic molecular subtypes of human breast cancer cells. NPJ Breast Cancer 2017;3:9. [PMID: 28649649 DOI: 10.1038/s41523-017-0009-7] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 6.5] [Reference Citation Analysis]
2 Lee KJ, Piett CG, Andrews JF, Mann E, Nagel ZD, Gassman NR. Defective base excision repair in the response to DNA damaging agents in triple negative breast cancer. PLoS One 2019;14:e0223725. [PMID: 31596905 DOI: 10.1371/journal.pone.0223725] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
3 Mukhopadhyay P, Horváth B, Kechrid M, Tanchian G, Rajesh M, Naura AS, Boulares AH, Pacher P. Poly(ADP-ribose) polymerase-1 is a key mediator of cisplatin-induced kidney inflammation and injury. Free Radic Biol Med 2011;51:1774-88. [PMID: 21884784 DOI: 10.1016/j.freeradbiomed.2011.08.006] [Cited by in Crossref: 62] [Cited by in F6Publishing: 59] [Article Influence: 6.2] [Reference Citation Analysis]
4 Vinayak S, Ford JM. PARP Inhibitors for the Treatment and Prevention of Breast Cancer. Curr Breast Cancer Rep 2010;2:190-7. [PMID: 22655123 DOI: 10.1007/s12609-010-0026-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
5 Yadav BS, Sharma SC, Chanana P, Jhamb S. Systemic treatment strategies for triple-negative breast cancer. World J Clin Oncol 2014;5:125-33. [PMID: 24829859 DOI: 10.5306/wjco.v5.i2.125] [Cited by in CrossRef: 72] [Cited by in F6Publishing: 65] [Article Influence: 10.3] [Reference Citation Analysis]
6 Chen YM, Liu Y, Wei HY, Lv KZ, Fu PF. Large intergenic non-coding RNA-ROR reverses gemcitabine-induced autophagy and apoptosis in breast cancer cells. Oncotarget 2016;7:59604-17. [PMID: 27449099 DOI: 10.18632/oncotarget.10730] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 9.3] [Reference Citation Analysis]
7 Karpel-Massler G, Pareja F, Aimé P, Shu C, Chau L, Westhoff MA, Halatsch ME, Crary JF, Canoll P, Siegelin MD. PARP inhibition restores extrinsic apoptotic sensitivity in glioblastoma. PLoS One 2014;9:e114583. [PMID: 25531448 DOI: 10.1371/journal.pone.0114583] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 4.6] [Reference Citation Analysis]
8 Robu M, Shah RG, Petitclerc N, Brind'Amour J, Kandan-Kulangara F, Shah GM. Role of poly(ADP-ribose) polymerase-1 in the removal of UV-induced DNA lesions by nucleotide excision repair. Proc Natl Acad Sci U S A 2013;110:1658-63. [PMID: 23319653 DOI: 10.1073/pnas.1209507110] [Cited by in Crossref: 106] [Cited by in F6Publishing: 94] [Article Influence: 13.3] [Reference Citation Analysis]
9 Vasmatzis G, Johnson SH, Knudson RA, Ketterling RP, Braggio E, Fonseca R, Viswanatha DS, Law ME, Kip NS, Ozsan N, Grebe SK, Frederick LA, Eckloff BW, Thompson EA, Kadin ME, Milosevic D, Porcher JC, Asmann YW, Smith DI, Kovtun IV, Ansell SM, Dogan A, Feldman AL. Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. Blood 2012;120:2280-9. [PMID: 22855598 DOI: 10.1182/blood-2012-03-419937] [Cited by in Crossref: 148] [Cited by in F6Publishing: 118] [Article Influence: 16.4] [Reference Citation Analysis]
10 Alluri P, Newman LA. Basal-like and triple-negative breast cancers: searching for positives among many negatives. Surg Oncol Clin N Am 2014;23:567-77. [PMID: 24882351 DOI: 10.1016/j.soc.2014.03.003] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 8.7] [Reference Citation Analysis]
11 Dubois F, Keller M, Hoflack J, Maille E, Antoine M, Westeel V, Bergot E, Quoix E, Lavolé A, Bigay-Game L, Pujol JL, Langlais A, Morin F, Zalcman G, Levallet G. Role of the YAP-1 Transcriptional Target cIAP2 in the Differential Susceptibility to Chemotherapy of Non-Small-Cell Lung Cancer (NSCLC) Patients with Tumor RASSF1A Gene Methylation from the Phase 3 IFCT-0002 Trial. Cancers (Basel) 2019;11:E1835. [PMID: 31766357 DOI: 10.3390/cancers11121835] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Siraj AK, Pratheeshkumar P, Parvathareddy SK, Divya SP, Al-Dayel F, Tulbah A, Ajarim D, Al-Kuraya KS. Overexpression of PARP is an independent prognostic marker for poor survival in Middle Eastern breast cancer and its inhibition can be enhanced with embelin co-treatment. Oncotarget 2018;9:37319-32. [PMID: 30647872 DOI: 10.18632/oncotarget.26470] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
13 Paterniti I, Scuderi SA, Casili G, Lanza M, Mare M, Giuffrida R, Colarossi C, Portelli M, Cuzzocrea S, Esposito E. Poly (ADP-Ribose) Polymerase Inhibitor, ABT888, Improved Cisplatin Effect in Human Oral Cell Carcinoma. Biomedicines 2021;9:771. [PMID: 34356835 DOI: 10.3390/biomedicines9070771] [Reference Citation Analysis]
14 Cañedo EC, Totten S, Ahn R, Savage P, MacNeil D, Hudson J, Autexier C, Deblois G, Park M, Witcher M, Ursini-Siegel J. p66ShcA potentiates the cytotoxic response of triple-negative breast cancers to PARP inhibitors. JCI Insight 2021;6:138382. [PMID: 33470989 DOI: 10.1172/jci.insight.138382] [Reference Citation Analysis]
15 Murai J, Zhang Y, Morris J, Ji J, Takeda S, Doroshow JH, Pommier Y. Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition. J Pharmacol Exp Ther 2014;349:408-16. [PMID: 24650937 DOI: 10.1124/jpet.113.210146] [Cited by in Crossref: 152] [Cited by in F6Publishing: 133] [Article Influence: 21.7] [Reference Citation Analysis]
16 Chung AH, Leisner TM, Dardis GJ, Bivins MM, Keller AL, Parise LV. CIB1 depletion with docetaxel or TRAIL enhances triple-negative breast cancer cell death. Cancer Cell Int 2019;19:26. [PMID: 30740034 DOI: 10.1186/s12935-019-0740-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
17 Croglio MP, Haake JM, Ryan CP, Wang VS, Lapier J, Schlarbaum JP, Dayani Y, Artuso E, Prandi C, Koltai H, Agama K, Pommier Y, Chen Y, Tricoli L, LaRocque JR, Albanese C, Yarden RI. Analogs of the novel phytohormone, strigolactone, trigger apoptosis and synergize with PARP inhibitors by inducing DNA damage and inhibiting DNA repair. Oncotarget 2016;7:13984-4001. [PMID: 26910887 DOI: 10.18632/oncotarget.7414] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
18 Wilkerson PM, Dedes KJ, Samartzis EP, Dedes I, Lambros MB, Natrajan R, Gauthier A, Piscuoglio S, Töpfer C, Vukovic V, Daley F, Weigelt B, Reis-Filho JS. Preclinical evaluation of the PARP inhibitor BMN-673 for the treatment of ovarian clear cell cancer. Oncotarget 2017;8:6057-66. [PMID: 28002809 DOI: 10.18632/oncotarget.14011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
19 Polotskaia A, Xiao G, Reynoso K, Martin C, Qiu WG, Hendrickson RC, Bargonetti J. Proteome-wide analysis of mutant p53 targets in breast cancer identifies new levels of gain-of-function that influence PARP, PCNA, and MCM4. Proc Natl Acad Sci U S A 2015;112:E1220-9. [PMID: 25733866 DOI: 10.1073/pnas.1416318112] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 7.7] [Reference Citation Analysis]
20 Srirangam A, Milani M, Mitra R, Guo Z, Rodriguez M, Kathuria H, Fukuda S, Rizzardi A, Schmechel S, Skalnik DG. The human immunodeficiency virus protease inhibitor ritonavir inhibits lung cancer cells, in part, by inhibition of survivin. J Thorac Oncol. 2011;6:661-670. [PMID: 21270666 DOI: 10.1097/jto.0b013e31820c9e3c] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
21 Yuan Y, Liao YM, Hsueh CT, Mirshahidi HR. Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP. J Hematol Oncol. 2011;4:16. [PMID: 21504625 DOI: 10.1186/1756-8722-4-16] [Cited by in Crossref: 87] [Cited by in F6Publishing: 79] [Article Influence: 8.7] [Reference Citation Analysis]
22 Alli E, Sharma VB, Hartman AR, Lin PS, McPherson L, Ford JM. Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells. BMC Pharmacol 2011;11:7. [PMID: 21771338 DOI: 10.1186/1471-2210-11-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
23 De Mei C, Ercolani L, Parodi C, Veronesi M, Lo Vecchio C, Bottegoni G, Torrente E, Scarpelli R, Marotta R, Ruffili R, Mattioli M, Reggiani A, Wade M, Grimaldi B. Dual inhibition of REV-ERBβ and autophagy as a novel pharmacological approach to induce cytotoxicity in cancer cells. Oncogene 2015;34:2597-608. [PMID: 25023698 DOI: 10.1038/onc.2014.203] [Cited by in Crossref: 64] [Cited by in F6Publishing: 57] [Article Influence: 9.1] [Reference Citation Analysis]
24 Mateo J, Ong M, Tan DS, Gonzalez MA, de Bono JS. Appraising iniparib, the PARP inhibitor that never was--what must we learn? Nat Rev Clin Oncol 2013;10:688-96. [PMID: 24129347 DOI: 10.1038/nrclinonc.2013.177] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 6.9] [Reference Citation Analysis]
25 Shah GM, Robu M, Purohit NK, Rajawat J, Tentori L, Graziani G. PARP Inhibitors in Cancer Therapy: Magic Bullets but Moving Targets. Front Oncol 2013;3:279. [PMID: 24294592 DOI: 10.3389/fonc.2013.00279] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
26 Yasukawa M, Fujihara H, Fujimori H, Kawaguchi K, Yamada H, Nakayama R, Yamamoto N, Kishi Y, Hamada Y, Masutani M. Synergetic Effects of PARP Inhibitor AZD2281 and Cisplatin in Oral Squamous Cell Carcinoma in Vitro and in Vivo. Int J Mol Sci 2016;17:272. [PMID: 26927065 DOI: 10.3390/ijms17030272] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 5.2] [Reference Citation Analysis]
27 Kim JS, Park IH, Lee KS, Ro J. Outcomes of palliative weekly low-dose gemcitabine-Cisplatin chemotherapy in anthracycline- and taxane- pretreated metastatic breast cancer patients. J Breast Cancer 2014;17:339-43. [PMID: 25548581 DOI: 10.4048/jbc.2014.17.4.339] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
28 Gu Y, Wang C, Zhu R, Yang J, Yuan W, Zhu Y, Zhou Y, Qin N, Shen H, Ma H, Wang H, Liu X, Hu Z. The cancer-testis gene, MEIOB, sensitizes triple-negative breast cancer to PARP1 inhibitors by inducing homologous recombination deficiency. Cancer Biol Med 2021;18:74-87. [PMID: 33628586 DOI: 10.20892/j.issn.2095-3941.2020.0071] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Telli ML, Timms KM, Reid J, Hennessy B, Mills GB, Jensen KC, Szallasi Z, Barry WT, Winer EP, Tung NM, Isakoff SJ, Ryan PD, Greene-Colozzi A, Gutin A, Sangale Z, Iliev D, Neff C, Abkevich V, Jones JT, Lanchbury JS, Hartman AR, Garber JE, Ford JM, Silver DP, Richardson AL. Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer. Clin Cancer Res. 2016;22:3764-3773. [PMID: 26957554 DOI: 10.1158/1078-0432.ccr-15-2477] [Cited by in Crossref: 343] [Cited by in F6Publishing: 164] [Article Influence: 68.6] [Reference Citation Analysis]
30 Liang S, Peng X, Li X, Yang P, Xie L, Li Y, Du C, Zhang G. Silencing of CXCR4 sensitizes triple-negative breast cancer cells to cisplatin. Oncotarget 2015;6:1020-30. [PMID: 25544759 DOI: 10.18632/oncotarget.2741] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
31 Jiang Y, Dai H, Li Y, Yin J, Guo S, Lin SY, McGrail DJ. PARP inhibitors synergize with gemcitabine by potentiating DNA damage in non-small-cell lung cancer.Int J Cancer. 2019;144:1092-1103. [PMID: 30152517 DOI: 10.1002/ijc.31770] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
32 Appleman LJ, Beumer JH, Jiang Y, Lin Y, Ding F, Puhalla S, Swartz L, Owonikoko TK, Donald Harvey R, Stoller R, Petro DP, Tawbi HA, Argiris A, Strychor S, Pouquet M, Kiesel B, Chen AP, Gandara D, Belani CP, Chu E, Ramalingam SS. Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies. Cancer Chemother Pharmacol 2019;84:1289-301. [PMID: 31549216 DOI: 10.1007/s00280-019-03960-w] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
33 Miao L, Yu Y, Ji Y, Zhang B, Yuan Z, Du Y, Zhu L, Wang R, Chen N, Yuan H. Association between BRCA1 P871L polymorphism and cancer risk: evidence from a meta-analysis. Oncotarget 2017;8:30587-94. [PMID: 28427168 DOI: 10.18632/oncotarget.15739] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
34 Yao H, He G, Yan S, Chen C, Song L, Rosol TJ, Deng X. Triple-negative breast cancer: is there a treatment on the horizon? Oncotarget 2017;8:1913-24. [PMID: 27765921 DOI: 10.18632/oncotarget.12284] [Cited by in Crossref: 143] [Cited by in F6Publishing: 127] [Article Influence: 47.7] [Reference Citation Analysis]
35 Wang ZC, Birkbak NJ, Culhane AC, Drapkin R, Fatima A, Tian R, Schwede M, Alsop K, Daniels KE, Piao H, Liu J, Etemadmoghadam D, Miron A, Salvesen HB, Mitchell G, DeFazio A, Quackenbush J, Berkowitz RS, Iglehart JD, Bowtell DD, Matulonis UA; Australian Ovarian Cancer Study Group. Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome. Clin Cancer Res 2012;18:5806-15. [PMID: 22912389 DOI: 10.1158/1078-0432.CCR-12-0857] [Cited by in Crossref: 108] [Cited by in F6Publishing: 64] [Article Influence: 12.0] [Reference Citation Analysis]
36 Tomao F, Papa A, Zaccarelli E, Rossi L, Caruso D, Minozzi M, Vici P, Frati L, Tomao S. Triple-negative breast cancer: new perspectives for targeted therapies. Onco Targets Ther 2015;8:177-93. [PMID: 25653541 DOI: 10.2147/OTT.S67673] [Cited by in Crossref: 85] [Cited by in F6Publishing: 54] [Article Influence: 14.2] [Reference Citation Analysis]
37 Ha K, Fiskus W, Choi DS, Bhaskara S, Cerchietti L, Devaraj SG, Shah B, Sharma S, Chang JC, Melnick AM, Hiebert S, Bhalla KN. Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells. Oncotarget 2014;5:5637-50. [PMID: 25026298 DOI: 10.18632/oncotarget.2154] [Cited by in Crossref: 90] [Cited by in F6Publishing: 80] [Article Influence: 15.0] [Reference Citation Analysis]
38 Quesada A, O'Valle F, Montoro-Molina S, Gómez-Morales M, Caba-Molina M, González JF, de Gracia MC, Osuna A, Vargas F, Wangensteen R. 5-aminoisoquinoline improves renal function and fibrosis during recovery phase of cisplatin-induced acute kidney injury in rats. Biosci Rep 2018;38:BSR20171313. [PMID: 29599129 DOI: 10.1042/BSR20171313] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
39 Sharma P, Barlow WE, Godwin AK, Parkes EE, Knight LA, Walker SM, Kennedy RD, Harkin DP, Logan GE, Steele CJ, Lambe SM, Badve S, Gökmen-Polar Y, Pathak HB, Isakova K, Linden HM, Porter P, Pusztai L, Thompson AM, Tripathy D, Hortobagyi GN, Hayes DF. Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial. J Clin Oncol 2019;37:3484-92. [PMID: 31657982 DOI: 10.1200/JCO.19.00693] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
40 Shao N, Shi Y, Yu L, Ye R, Shan Z, Zhang Z, Zhang Y, Lin Y. Prospect for Application of PARP Inhibitor in Patients with HER2 Negative Breast Cancer. Int J Biol Sci 2019;15:962-72. [PMID: 31182917 DOI: 10.7150/ijbs.30721] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
41 Zhou X. p73 G4C14-to-A4T14 polymorphisms are positively correlated with triple-negative breast cancer in southwestern China. Med Oncol 2013;30:515. [PMID: 23443851 DOI: 10.1007/s12032-013-0515-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
42 Kong P, Chen L, Yu M, Tao J, Liu J, Wang Y, Pan H, Zhou W, Wang S. miR-3178 inhibits cell proliferation and metastasis by targeting Notch1 in triple-negative breast cancer. Cell Death Dis 2018;9:1059. [PMID: 30333478 DOI: 10.1038/s41419-018-1091-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
43 Anders CK, Winer EP, Ford JM, Dent R, Silver DP, Sledge GW, Carey LA. Poly(ADP-Ribose) polymerase inhibition: “targeted” therapy for triple-negative breast cancer. Clin Cancer Res. 2010;16:4702-4710. [PMID: 20858840 DOI: 10.1158/1078-0432.ccr-10-0939] [Cited by in Crossref: 105] [Cited by in F6Publishing: 67] [Article Influence: 9.5] [Reference Citation Analysis]
44 Capdevila-Busquets E, Badiola N, Arroyo R, Alcalde V, Soler-López M, Aloy P. Breast cancer genes PSMC3IP and EPSTI1 play a role in apoptosis regulation. PLoS One 2015;10:e0115352. [PMID: 25590583 DOI: 10.1371/journal.pone.0115352] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
45 Mann M, Kumar S, Sharma A, Chauhan SS, Bhatla N, Kumar S, Bakhshi S, Gupta R, Kumar L. PARP-1 inhibitor modulate β-catenin signaling to enhance cisplatin sensitivity in cancer cervix. Oncotarget 2019;10:4262-75. [PMID: 31303961 DOI: 10.18632/oncotarget.27008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
46 Prabhakaran P, Hassiotou F, Blancafort P, Filgueira L. Cisplatin induces differentiation of breast cancer cells. Front Oncol 2013;3:134. [PMID: 23761858 DOI: 10.3389/fonc.2013.00134] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.5] [Reference Citation Analysis]
47 Wilkerson MD, Yin X, Walter V, Zhao N, Cabanski CR, Hayward MC, Miller CR, Socinski MA, Parsons AM, Thorne LB. Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylation. PLoS One. 2012;7:e36530. [PMID: 22590557 DOI: 10.1371/journal.pone.0036530] [Cited by in Crossref: 145] [Cited by in F6Publishing: 112] [Article Influence: 16.1] [Reference Citation Analysis]
48 Yadav BS, Chanana P, Jhamb S. Biomarkers in triple negative breast cancer: A review. World J Clin Oncol 2015;6:252-63. [PMID: 26677438 DOI: 10.5306/wjco.v6.i6.252] [Cited by in CrossRef: 58] [Cited by in F6Publishing: 58] [Article Influence: 9.7] [Reference Citation Analysis]
49 Lu Y, Liu Y, Pang Y, Pacak K, Yang C. Double-barreled gun: Combination of PARP inhibitor with conventional chemotherapy. Pharmacol Ther 2018;188:168-75. [PMID: 29621593 DOI: 10.1016/j.pharmthera.2018.03.006] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
50 Zimmer AS, Gillard M, Lipkowitz S, Lee JM. Update on PARP Inhibitors in Breast Cancer. Curr Treat Options Oncol 2018;19:21. [PMID: 29644491 DOI: 10.1007/s11864-018-0540-2] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 14.7] [Reference Citation Analysis]
51 Atipairin A, Ratanaphan A. In Vitro Enhanced Sensitivity to Cisplatin in D67Y BRCA1 RING Domain Protein. Breast Cancer (Auckl) 2011;5:201-8. [PMID: 22084573 DOI: 10.4137/BCBCR.S8184] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
52 Hastak K, Bhutra S, Parry R, Ford JM. Poly (ADP-ribose) polymerase inhibitor, an effective radiosensitizer in lung and pancreatic cancers. Oncotarget 2017;8:26344-55. [PMID: 28412751 DOI: 10.18632/oncotarget.15464] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
53 Bucur O, Stancu AL, Khosravi-Far R, Almasan A. Analysis of apoptosis methods recently used in Cancer Research and Cell Death & Disease publications. Cell Death Dis 2012;3:e263. [PMID: 22297295 DOI: 10.1038/cddis.2012.2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
54 Pierce A, McGowan PM, Cotter M, Mullooly M, O'Donovan N, Rani S, O'Driscoll L, Crown J, Duffy MJ. Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines. Cancer Biol Ther 2013;14:537-45. [PMID: 23760496 DOI: 10.4161/cbt.24349] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
55 Clark CC, Weitzel JN, O'Connor TR. Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models. Mol Cancer Ther 2012;11:1948-58. [PMID: 22778154 DOI: 10.1158/1535-7163.MCT-11-0597] [Cited by in Crossref: 53] [Cited by in F6Publishing: 21] [Article Influence: 5.9] [Reference Citation Analysis]
56 Ávila-Arroyo S, Nuñez GS, García-Fernández LF, Galmarini CM. Synergistic Effect of Trabectedin and Olaparib Combination Regimen in Breast Cancer Cell Lines. J Breast Cancer 2015;18:329-38. [PMID: 26770239 DOI: 10.4048/jbc.2015.18.4.329] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
57 Liu L, Zhou W, Cheng CT, Ren X, Somlo G, Fong MY, Chin AR, Li H, Yu Y, Xu Y, O'Connor ST, O'Connor TR, Ann DK, Stark JM, Wang SE. TGFβ induces "BRCAness" and sensitivity to PARP inhibition in breast cancer by regulating DNA-repair genes. Mol Cancer Res 2014;12:1597-609. [PMID: 25103497 DOI: 10.1158/1541-7786.MCR-14-0201] [Cited by in Crossref: 33] [Cited by in F6Publishing: 22] [Article Influence: 4.7] [Reference Citation Analysis]
58 Ratanaphan A. A DNA repair BRCA1 estrogen receptor and targeted therapy in breast cancer. Int J Mol Sci 2012;13:14898-916. [PMID: 23203101 DOI: 10.3390/ijms131114898] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
59 Ryu H, Kim HJ, Song JY, Hwang SG, Kim JS, Kim J, Bui THN, Choi HK, Ahn J. A Small Compound KJ-28d Enhances the Sensitivity of Non-Small Cell Lung Cancer to Radio- and Chemotherapy. Int J Mol Sci 2019;20:E6026. [PMID: 31795418 DOI: 10.3390/ijms20236026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
60 Reddy S, Raffin M, Kaklamani V. Targeting angiogenesis in metastatic breast cancer. Oncologist 2012;17:1014-26. [PMID: 22843553 DOI: 10.1634/theoncologist.2012-0043] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
61 Sonnenblick A, de Azambuja E, Azim HA Jr, Piccart M. An update on PARP inhibitors--moving to the adjuvant setting. Nat Rev Clin Oncol 2015;12:27-41. [PMID: 25286972 DOI: 10.1038/nrclinonc.2014.163] [Cited by in Crossref: 234] [Cited by in F6Publishing: 192] [Article Influence: 33.4] [Reference Citation Analysis]
62 Telli ML, Jensen KC, Vinayak S, Kurian AW, Lipson JA, Flaherty PJ, Timms K, Abkevich V, Schackmann EA, Wapnir IL, Carlson RW, Chang PJ, Sparano JA, Head B, Goldstein LJ, Haley B, Dakhil SR, Reid JE, Hartman AR, Manola J, Ford JM. Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105. J Clin Oncol 2015;33:1895-901. [PMID: 25847929 DOI: 10.1200/JCO.2014.57.0085] [Cited by in Crossref: 145] [Cited by in F6Publishing: 79] [Article Influence: 24.2] [Reference Citation Analysis]
63 Omarini C, Guaitoli G, Pipitone S, Moscetti L, Cortesi L, Cascinu S, Piacentini F. Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going. Cancer Manag Res 2018;10:91-103. [PMID: 29391830 DOI: 10.2147/CMAR.S146658] [Cited by in Crossref: 36] [Cited by in F6Publishing: 24] [Article Influence: 12.0] [Reference Citation Analysis]
64 Bryant C, Rawlinson R, Massey AJ. Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers. BMC Cancer 2014;14:570. [PMID: 25104095 DOI: 10.1186/1471-2407-14-570] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 8.9] [Reference Citation Analysis]
65 Maxwell KN, Domchek SM. Cancer treatment according to BRCA1 and BRCA2 mutations. Nat Rev Clin Oncol 2012;9:520-8. [PMID: 22825375 DOI: 10.1038/nrclinonc.2012.123] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 5.8] [Reference Citation Analysis]
66 Polotskaia A, Hoffman S, Krett NL, Shanmugam M, Rosen ST, Bargonetti J. 8-Amino-adenosine activates p53-independent cell death of metastatic breast cancers. Mol Cancer Ther 2012;11:2495-504. [PMID: 22973058 DOI: 10.1158/1535-7163.MCT-12-0085] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
67 Chuang HC, Kapuriya N, Kulp SK, Chen CS, Shapiro CL. Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells. Breast Cancer Res Treat 2012;134:649-59. [PMID: 22678161 DOI: 10.1007/s10549-012-2106-5] [Cited by in Crossref: 71] [Cited by in F6Publishing: 60] [Article Influence: 7.9] [Reference Citation Analysis]
68 Alli E, Solow-Cordero D, Casey SC, Ford JM. Therapeutic targeting of BRCA1-mutated breast cancers with agents that activate DNA repair. Cancer Res 2014;74:6205-15. [PMID: 25217519 DOI: 10.1158/0008-5472.CAN-14-1716] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 2.1] [Reference Citation Analysis]